Harrow Health, Inc. (HROW)

NASDAQ • Healthcare

$28.44

+$0.29 (+1.0%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$27.76

Previous Close$28.44

Day Range$27.14 - $28.56

Avg. Volume (3M)633.4K

Market Cap$1B

52 Week Range

$26.96$54.85

Next EarningsIn 15 daysNov 9, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$70.6M100%

Gross Profitminus cost of goods$50.3M71%

In plain terms: out of every $100 in revenue, Harrow Health, Inc. currently loses $24.

Fundamentals & Financials

Revenue (TTM)

$275.5M

Net Income (TTM)

-$37.2M

EPS (TTM)

-$0.99

ROA (TTM)

-8.93%

Current Ratio

2.24

Dividend Yield

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+1754.3%Q3 2025$0.14

-86.4%Q4 2025$0.03

-55.0%Q1 2026$0.18

-72.1%Q2 2026-$0.74

-157.3%Q3 2026-$0.46

Nov 9

in 15 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Next report — what to expect

Harrow Health, Inc. (HROW) reports on November 9, 2026. Wall Street expects EPS of $0.16 on revenue of $99.1 million. For trailing context, revenue grew +10.9% year over year last quarter. HROW has beaten EPS in 2 of 8 most recent quarters, making the EPS outcome a key item to watch.

View full earnings history

About Harrow Health, Inc.

Harrow Health, Inc. (NASDAQ: HROW) is a healthcare company that develops and sells specialty ophthalmic pharmaceuticals and compounded medicines. Through its ImprimisRx brand and products such as DEXYCU, it serves eye-care needs including post-operative inflammation management, and it generated $272.3 million in FY2025 revenue.

Name

Harrow Health, Inc.

CEO

Mark L. Baum

Website

www.harrow.com

Industry

Healthcare

Year Founded

2006

Employees

373

Today's Snapshot

AI-generated

HROW closed 1% above yesterday's close, outperforming a weaker sector. Volume was about a quarter more than its usual level.

Trading Volume

Above 10d avg 610.3K

852.5K

vs S&P 500 Today

Outperforming Market

+1.55%

Updated: October 23, 2026 at 20:22 UTC

Technical Indicators

0 Buy3 Neutral5 Sell

HROW near 28.44 exhibits pronounced weakness across multiple indicators. ADX at 47.8 signals a strong downtrend while short-term momentum is negative and MACD is on the bearish side, reflecting selling pressure. The stock trades below most medium- and long-term moving averages despite marginally mixed very short-term signals, leaving the broader bias tilted lower. OBV is negative, indicating that volume has accompanied the decline, and volatility is moderate with ATR about 1.38 (4.9%). Technical takeaway: Strong Sell — persistent trend and volume support the bearish stance.

All signals

EMA (5 indicators)$28.50 - $38.03
Sell
RSI (14)36.21
Neutral
Stochastic %K (14, 3, 3)30.31
Neutral
MACD Level (12, 26)-1.70
Neutral

Peers & Related Assets

KODKodiak Sciences Inc.

$87.63+2.2%

TARSTarsus Pharmaceuticals, Inc.

$68.2-5.4%

OCULOcular Therapeutix, Inc.

$6.5-1.7%

EYPTEyePoint Pharmaceuticals, Inc.

$0.4-5.5%

BLCOBausch + Lomb Corporation

OCSOculis Holding AG

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.